Akebia Therapeutics Inc AKBA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EST
3.47quote price arrow up+0.01 (+0.29%)
Volume
14,370
Close
3.46quote price arrow down-0.01 (-0.29%)
Volume
7,099,826
52 week range
2.09 - 13.71

...

Loading . . .

KEY STATS

  • Open3.45
  • Day High3.53
  • Day Low3.24
  • Prev Close3.47
  • 52 Week High13.71
  • 52 Week High Date07/07/20
  • 52 Week Low2.09
  • 52 Week Low Date10/30/20
  • Market Cap500.11M
  • Shares Out144.54M
  • 10 Day Average Volume7.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.89
  • 1 Year % Change-60.82

RATIOS/PROFITABILITY

  • EPS (TTM)-2.77
  • P/E (TTM)-1.25
  • Fwd P/E (NTM)-2.80
  • EBITDA (MRQ)-234.851M
  • ROE (MRQ)-99.54%
  • Revenue (MRQ)308.16M
  • Gross Margin (MRQ)59.34%
  • Net Margin (MRQ)-126.86%
  • Debt To Equity (MRQ)24.09%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Akebia Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the...
Adrian Adams
Non-Executive Chairman
John Butler
President
Michel Dahan
Chief Operating Officer
David Spellman
Chief Financial Officer
Address
245 1st St
Cambridge, MA
02142-1200
United States